BIOTECanada :: Early Stage Company of the Year

Membership

Early Stage Company of the Year - Health

Award Description

The recipients of this award are pre-commercialization companies and are recognized for their potential. They will have distinguished themselves from their peers with demonstrated technology innovation and achieved milestones.

Allon Therapeutics Inc. - 2011 Early Stage Company of the Year - Health Winner

Patricia Massetti, Vice-President, Public Affairs & Patient Access, Merck Canada Inc. presents
Gordon McCauley of Allon Therapeutics Inc. with the award for
EARLY STAGE COMPANY OF THE YEAR - HEALTH.

Allon Therapeutics Inc. is focused on bringing to market innovative central nervous system therapies. Allon’s lead drug davunetide, is proceeding in a pivotal clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA. This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment (a precursor to Alzheimer’s disease), cognitive impairment associated with schizophrenia, and positive biomarker data.

Progress in Allon’s PSP program includes:

Allon began enrolling patients in a pivotal clinical trial
FDA and Allon agree on a Special Protocol Assessment (SPA)
Allon announced that pilot clinical trial meets primary endpoint with Allon’s davunetide
Allon received Orphan drug designation for davunetide in the United States (FDA) and the European Union, the world’s two largest pharmaceutical markets
Allon received Fast track status in the U.S. (FDA)

Allon believes this next trial will not just provide data for a potential approval in PSP, but will also define the opportunity in other tau-related diseases, such as Alzheimer’s, schizophrenia, Parkinson’s and several types of frontotemporal dementia.

The Company is listed on the Toronto Stock Exchange (TSX: NPC) and based in Vancouver.  Visit their website for more information www.allontherapeutics.com

2001- 2010 Past Award Recipients

2010 - iCo Therapeutics Inc. (see profile)
2009 - Medicago Inc. (see profile)
2008 - Xenon Pharmaceuticals
*2007 - Chemaphor Inc.
2006 - Rimon Therapeutics Ltd.
2005 - ImmunoVaccine Technologies Inc., Halifax, NS
2005 - Trillium Therapeutics Inc., Toronto, ON
2004 - Arc Pharmaceuticals Inc, Vancouver, BC
2004 - Clera Inc., Toronto, ON
2004 - Generex Biotechnology, Toronto, ON
2003 - GB Therapeutics (now CITA Neuropharma Inc.), Mississauga, ON
2003 - Zelos Therapeutics, Ottawa, ON
2003 - Zinc Therapeutics, Toronto, ON

*Prior to 2008, BIOTECanada's annual awards program was known as the National Biotechnology Awards with recognition for companies and this award was called "Promising Early Stage company(s) Recognition".